Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease
Open Access
- 1 April 1989
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 59 (4) , 645-649
- https://doi.org/10.1038/bjc.1989.131
Abstract
From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1. The drug dosage per unit body surface (or 'dose density') significantly correlates with the drop in leukocyte count (P less than 0.001) and the tumour regression at the end of the induction course (P = 0.020). Disease-free survival is significantly related to dose density (P = 0.050) but not to dose intensity calculated on the duration of treatment (P = 0.240). However, after exclusion of three marginal recurrences due to border-line radiotherapy, the dose intensity significantly correlates with the disease-free survival (P = 0.031) and with the duration of complete remission (r = 0.870).Keywords
This publication has 19 references indexed in Scilit:
- Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I–IIIAEuropean Journal of Cancer and Clinical Oncology, 1988
- Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.British Journal of Clinical Pharmacology, 1980
- Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) V.S. CVPP PLUS CCNU (CCVPP) in Hodgkin's diseaseCancer, 1979
- Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects.1978
- Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's diseaseCancer, 1977
- Combined chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease.An alternative program to MOPPCancer, 1976
- [Significance of chemotherapy complementary to radiotherapy in stages I and II in Hodgkin's disease].1975
- [Common language for expression of therapeutic results in oncology].1974
- Chimiothérapie de la maladie de Hodgkin associant procarbazine, vinblastine, cyclophosphamide et méthyl-prednisoloneZeitschrift für Krebsforschung und Klinische Onkologie, 1973
- Clinical Evaluation and Radiotherapeutic Management of Hodgkin's Disease and the Malignant LymphomasNew England Journal of Medicine, 1968